Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Sagimet Biosciences Inc.NASDAQ: SGMT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows in line with its trailing trend
Q1 FY2026 selling, general & admin of $4.72M rose 4.3% year over year, behind the +5.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 17.0% from the prior quarter. Over 3 fiscal years it compounded at +42.7% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $232.92K (-98.7%) for the fiscal year ending Dec 2026, a slowdown from the +11.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.72M+17.0% QoQ
- Last fiscal yearDec 2025
- $17.84M+11.4% YoY
- LTMMar 2026
- $18.03M+5.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 17.84M USD
- Year-over-year change
- +11.4%
- 4-year CAGR
- +42.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.84M | +11.4% |
| FY2024 | 2024-12-31 | 16.01M | +23.5% |
| FY2023 | 2023-12-31 | 12.96M | +111.3% |
| FY2022 | 2022-12-31 | 6.14M | +40.1% |
| FY2021 | 2021-12-31 | 4.38M | — |
Selling, General & Admin vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's LTM Mar 2026 selling, general & admin of $18.03M is the lowest of the 11 companies compared; the peer median is $34.17M.
- Its year-over-year change of +5.9% is the 4th highest of 11, against a peer median of -0.6%.
- Over three fiscal years its annual growth of +42.7% compares with a peer median of +5.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.7B | +29505.3% | +3.5% | — | |
| LTM Mar 2026 | $43.57M | -11.6% | +0.0% | 96.1% | |
| LTM Mar 2026 | $40.9M | +4.0% | +10.2% | 712.8% | |
| LTM Mar 2026 | $36.17M | -2.1% | +6.6% | 99.1% | |
ZURAZura Bio Limited | LTM Mar 2026 | $35.14M | +1.0% | +112.2% | — |
| LTM Mar 2026 | $33.2M | +76.0% | +43.8% | — | |
| LTM Mar 2026 | $30.28M | -34.0% | -12.3% | — | |
| LTM Mar 2026 | $27.31M | -10.2% | +10.9% | 1354.8% | |
| LTM Mar 2026 | $26.89M | -3.6% | -3.6% | 95.3% | |
| LTM Mar 2026 | $19.78M | +10.8% | -6.4% | 27.8% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $18.03M | +5.9% | +42.7% | — |
| Peer median (excluding SGMT) | $34.17M | -0.6% | +5.1% | 97.6% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 2M | 0 | 0 |
| Gross Margin | — | — | 100.0% | — | — |
| Research & Development | 19.34M | 24.92M | 19.78M | 38.44M | 39.05M |
| Selling, General & Admin | 4.38M | 6.14M | 12.96M | 16.01M | 17.84M |
| Operating Expenses | 23.72M | 31.06M | 32.74M | 54.45M | 56.89M |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| EBITDA | (24.44M) | (30.37M) | (27.88M) | (45.57M) | (51.04M) |
| EBITDA Margin | — | — | -1393.8% | — | — |
| Operating Income | (23.72M) | (31.06M) | (30.74M) | (54.45M) | (56.89M) |
| Operating Margin | — | — | -1537.0% | — | — |
| Interest Income | 26K | 553K | 2.86M | 8.89M | 5.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (723K) | 556K | 2.86M | 8.89M | 5.85M |
| Income Before Tax | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Pre-Tax Margin | — | — | -1393.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Net Margin | — | — | -1393.8% | — | — |
| EPS (Basic) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| EPS (Diluted) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| Weighted Avg Shares | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
| Weighted Avg Shares (Diluted) | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.